0001209191-21-071194.txt : 20211223 0001209191-21-071194.hdr.sgml : 20211223 20211223210032 ACCESSION NUMBER: 0001209191-21-071194 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211222 FILED AS OF DATE: 20211223 DATE AS OF CHANGE: 20211223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Taylor Stacy L CENTRAL INDEX KEY: 0001799081 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 211518710 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVENUE E SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-22 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001799081 Taylor Stacy L C/O ADAPTIVE BIOTECHNOLOGIES 1165 EASTLAKE AVE E SEATTLE WA 98102 0 1 0 0 SVP and General Counsel Common Stock 2021-12-22 4 M 0 10130 6.55 A 25166 D Common Stock 2021-12-22 4 M 0 5208 7.80 A 30374 D Common Stock 2021-12-22 4 S 0 15338 30.00 D 15036 D Stock Option (Right to Buy) 6.55 2021-12-22 4 M 0 10130 0.00 D 2028-04-24 Common Stock 10130 5313 D Stock Option (Right to Buy) 7.80 2021-12-22 4 M 0 5208 0.00 D 2029-04-23 Common Stock 5208 17709 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Stacy L. Taylor by Eric Billings as attorney-in-fact 2021-12-23